Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy [Yahoo! Finance]
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds [Yahoo! Finance]
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis [Yahoo! Finance]